Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial

Gregory Y H Lip, Julius Nikorowitsch, Susanne Sehner, Nina Becher, Emanuele Bertaglia, Carina Blomstrom-Lundqvist, Axel Brandes, Vincent Beuger, Melanie Calvert, A John Camm, Gregory Chlouverakis, Gheorghe-Andrei Dan, Wolfgang Dichtl, Hans Christoph Diener, Alexander Fierenz, Andreas Goette, Joris R de Groot, Astrid Hermans, Andrzej Lubinski, Eloi MarijonBéla Merkely, Lluís Mont, Ann-Kathrin Ozga, Kim Rajappan, Andrea Sarkozy, Daniel Scherr, Renate B Schnabel, Ulrich Schotten, Emmanuel Simantirakis, Tobias Toennis, Panos Vardas, Dan Wichterle, Antonia Zapf, Paulus Kirchhof*, NOAH-AFNET 6 investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article numberehae225
Number of pages5
JournalEuropean Heart Journal
DOIs
Publication statusE-pub ahead of print - 9 Apr 2024

Keywords

  • Anticoagulation
  • Atrial fibrillation
  • Atrial high-rate episodes
  • Bleeding
  • CHA2DS2-VASc score
  • Device-detected atrial fibrillation
  • Kidney function
  • NOAH-AFNET 6
  • Stroke

Cite this